Brivaracetam
Who holds supplier records for Brivaracetam? 25 organisations hold a current record for Brivaracetam: an active US FDA Type II Drug Master File or a CEP. 14 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: India (13) and China (7); not recorded for 5.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Brivaracetam: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/brivaracetam
Reading the evidence
- 25 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- Most recorded organisations are in India
13 of the 20 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.
- 14 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Brivaracetam expires 9 Apr 2030. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (25)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Brivaracetam. Country is the organisation's recorded country, not necessarily the manufacturing site.
- AMI LIFESCIENCES PRIVATE LTDIndiaCEP Company GMP cert on recordActive DMF 36655, 41918 · latest filing May 2025
- HONOUR LAB LTDIndiaCEP Company GMP cert on recordActive DMF 34569, 42544 · latest filing Sept 2025
- Yangzhou Aurisco Pharmaceutical Co.,Ltd.ChinaCEPActive DMF 37329, 40342 · latest filing Sept 2024
- Zhejiang Huahai Pharmaceutical Co., Ltd.ChinaCEP Company GMP cert on recordActive DMF 37524, 40761 · latest filing Oct 2024
- ALIVUS LIFE SCIENCES LTDIndiaCEP Company GMP cert on recordActive DMF 38597 · latest filing Nov 2023
- APITORIA PHARMA PRIVATE LTDIndiaCEP Company GMP cert on recordActive DMF 40678 · latest filing Dec 2024
- Chengda Pharmaceuticals Co., Ltd.ChinaCEPActive DMF 37821 · latest filing Jul 2023
- Divis LaboratoriesIndiaCEP Company GMP cert on recordActive DMF 41570 · latest filing Mar 2025
- LEE PHARMA LTDIndiaCEP Company GMP cert on recordActive DMF 39008 · latest filing Oct 2023
- Maithri Laboratories Private LimitedIndiaCEP Company GMP cert on recordActive DMF 33709 · latest filing Mar 2019
- MICRO LABS LTDIndiaCEP Company GMP cert on recordActive DMF 34585 · latest filing Feb 2020
- OPTIMUS DRUGS PRIVATE LTDIndiaCEPActive DMF 36649 · latest filing Apr 2022
- SOLARA ACTIVE PHARMA SCIENCES LTDIndiaCEP Company GMP cert on recordActive DMF 36304 · latest filing Sept 2021
- ATILUS PHARMA PRIVATE LTDActive DMF 44646 · latest filing Aug 2026
- Aurisco Pharmaceutical Co.,ltdChina Company GMP cert on recordActive DMF 34511 · latest filing Jan 2020
- BEIJING HOPE PHARMACEUTICAL CO LTDActive DMF 37516 · latest filing Sept 2022
- CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTDCompany GMP cert on recordActive DMF 41491 · latest filing Mar 2025
- EMNAR PHARMA PRIVATE LTDIndiaActive DMF 44011 · latest filing Apr 2026
- LUPIN MANUFACTURING SOLUTIONS LTDActive DMF 34402 · latest filing Dec 2019
- MAITHRI DRUGS PRIVATE LTDIndia Company GMP cert on recordActive DMF 44123 · latest filing May 2026
- RUYUAN HEC PHARM CO LTDActive DMF 34398 · latest filing Jan 2020
- Shaoxing Jingxin Pharmaceutical Co., Ltd.ChinaActive DMF 36409 · latest filing Dec 2021
- Zhejiang Apeloa Jiayuan Pharmaceutical Co., Ltd.ChinaActive DMF 42511 · latest filing Sept 2025
- Zydus Lifesciences LimitedIndia Company GMP cert on recordActive DMF 34405 · latest filing Dec 2019
- ChinaCEP
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Valid CEP holder entries (14)
Certificates of Suitability on the EDQM register for Brivaracetam, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 16 certificates in total, including withdrawn, expired, suspended and repeat certificates.
| Holder | Country | Certificate | Issued | EU GMP at holder's address |
|---|---|---|---|---|
| HONOUR LAB LIMITED Hyderabad | IN | CEP 2024-533 - Rev 00 Brivaracetam | Nov 2026 | — |
| AMI LIFESCIENCES PRIVATE LIMITED Vadodara | IN | CEP 2025-171 - Rev 01 Brivaracetam, Process II | Nov 2026 | Inspected Oct 2025 Slovakia |
| LEE PHARMA LIMITED Hyderabad | IN | CEP 2024-474 - Rev 00 Brivaracetam | Sept 2026 | — |
| OPTIMUS DRUGS PRIVATE LIMITED Hyderabad | IN | CEP 2025-132 - Rev 00 Brivaracetam | Aug 2026 | — |
| APITORIA PHARMA PRIVATE LIMITED Hyderabad | IN | CEP 2024-596 - Rev 01 Brivaracetam, Form-A | Jul 2026 | — |
| SOLARA ACTIVE PHARMA SCIENCES LIMITED Chennai | IN | CEP 2024-186 - Rev 00 Brivaracetam | Jun 2026 | — |
| DIVI'S LABORATORIES LIMITED Hyderabad | IN | CEP 2025-021 - Rev 00 Brivaracetam | Jun 2026 | — |
| ZHEJIANG TIANYU PHARMACEUTICAL CO., LTD. Taizhou City | CN | CEP 2025-089 - Rev 01 Brivaracetam | May 2026 | — |
| ALIVUS LIFE SCIENCES LIMITED Mumbai | IN | CEP 2024-088 - Rev 02 Brivaracetam | May 2026 | — |
| MICRO LABS LIMITED Bengaluru | IN | CEP 2025-533 - Rev 00 Brivaracetam, Process-II | Mar 2026 | — |
| ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. Taizhou | CN | CEP 2024-064 - Rev 02 Brivaracetam, Non-micronised and micronised | Feb 2026 | Inspected May 2026 Italy |
| CHENGDA PHARMACEUTICALS CO., LTD. Jiashan | CN | CEP 2024-227 - Rev 00 Brivaracetam | Dec 2025 | — |
| MAITHRI LABORATORIES PRIVATE LIMITED Gaddapotharam Village | IN | CEP 2024-061 - Rev 01 Brivaracetam, Micronised and Non-micronised | Jul 2025 | — |
| YANGZHOU AURISCO PHARMACEUTICAL CO., LTD. Yangzhou City | CN | CEP 2024-375 - Rev 00 Brivaracetam | Mar 2025 | — |
The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.
Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (56 listed products contain Brivaracetam). The latest listed patent expires 9 Apr 2030. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Overview
Brivaracetam is an anticonvulsant medication used to treat epilepsy. It is a derivative of levetiracetam with a racetam chemical structure.
Chemical identity
- IUPAC name
- (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide
- Canonical SMILES
- CCC[C@@H]1CC(=O)N(C1)[C@@H](CC)C(=O)N
- InChIKey
- MSYKRHVOOPPJKU-BDAKNGLRSA-N
- Synonyms
- Briviact API, briviact, dea no. 2710, ucb 34714
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Mechanism of action
- Epoxide Hydrolase Inhibitors
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Brivaracetam?
25 organisations hold an active US FDA Type II Drug Master File or a CEP for Brivaracetam: AMI LIFESCIENCES PRIVATE LTD (India), HONOUR LAB LTD (India), Yangzhou Aurisco Pharmaceutical Co.,Ltd. (China), Zhejiang Huahai Pharmaceutical Co., Ltd. (China), ALIVUS LIFE SCIENCES LTD (India), APITORIA PHARMA PRIVATE LTD (India), Chengda Pharmaceuticals Co., Ltd. (China) and Divis Laboratories (India), and 17 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Brivaracetam Drug Master Files are active?
AMI LIFESCIENCES PRIVATE LTD (DMF 36655, 41918), HONOUR LAB LTD (DMF 34569, 42544), Yangzhou Aurisco Pharmaceutical Co.,Ltd. (DMF 37329, 40342), Zhejiang Huahai Pharmaceutical Co., Ltd. (DMF 37524, 40761), ALIVUS LIFE SCIENCES LTD (DMF 38597), APITORIA PHARMA PRIVATE LTD (DMF 40678), Chengda Pharmaceuticals Co., Ltd. (DMF 37821) and Divis Laboratories (DMF 41570) and 16 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
Does Brivaracetam have a European Certificate of Suitability?
Yes. 14 organisations hold a valid CEP for Brivaracetam on the EDQM register, including HONOUR LAB LIMITED Hyderabad (IN), AMI LIFESCIENCES PRIVATE LIMITED Vadodara (IN), LEE PHARMA LIMITED Hyderabad (IN), OPTIMUS DRUGS PRIVATE LIMITED Hyderabad (IN), APITORIA PHARMA PRIVATE LIMITED Hyderabad (IN) and SOLARA ACTIVE PHARMA SCIENCES LIMITED Chennai (IN) and 8 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.
Does the FDA Orange Book list patents for products containing Brivaracetam?
Yes. The latest patent listed for an approved US product containing Brivaracetam expires 9 Apr 2030, across 56 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Brivaracetam supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Brivaracetam?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.